- My Forums
- Tiger Rant
- LSU Recruiting
- SEC Rant
- Saints Talk
- Pelicans Talk
- More Sports Board
- Winter Olympics
- Fantasy Sports
- Golf Board
- Soccer Board
- O-T Lounge
- Tech Board
- Home/Garden Board
- Outdoor Board
- Health/Fitness Board
- Movie/TV Board
- Book Board
- Music Board
- Political Talk
- Money Talk
- Fark Board
- Gaming Board
- Travel Board
- Food/Drink Board
- Ticket Exchange
- TD Help Board
Customize My Forums- View All Forums
- Show Left Links
- Topic Sort Options
- Trending Topics
- Recent Topics
- Active Topics
Started By
Message
BTCY Watch Notice
Posted on 4/18/23 at 8:20 am
Posted on 4/18/23 at 8:20 am
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets.
There is an ongoing shift in healthcare towards preventive care, which Biotricity is leveraging to modernize chronic care & disease management.
The company believes its diagnostic and post-diagnostic solutions help reduce healthcare costs and detect anomalies earlier than existing monitoring solutions and provide faster and better reporting, as well. BTCY has expanded its salesforce in 2022 and targets further penetration into doctor’s offices and clinics with the recent launch of Biotres and the upcoming launch of other products. The company believes its tech platform is disrupting the traditional cardiac care model. With Biotricity’stechnology, cardiac patients can access advanced diagnostics from their homes using Biotricity devices, and thereby minimize visits to the cardiologist or hospital to times when therapeutic treatment or procedures are needed. The company’s lead product, Bioflux, is designed to detect an arrhythmia, heart attack, ventricular or atrial issue faster and transmit the information to a call center to prevent a traumatic health event faster than a conventional Holter device.
As BTCY moves to grow its share in the cardiac health cloud service niche, the company also seeks to expand horizontally beyond the cardiac market. Biotricity believes its emerging ecosystem offers a user- friendly platform that can be applied to help people suffering with diabetes, obesity, hypertension, sleep apnea, pain management and potentially many other areas.
The company launched Biotres earlier this year. It is a wearable wireless 3-lead patch device for continuous recording of ECG heart data and wider array of arrythmia monitoring.
As BTCY initiatives measures to grow its share in the cardiac health cloud service niche, the company also seeks to expand horizontally beyond cardiac and believes its emerging ecosystem offers a user-friendly platform that can be applied to monitor and assist people suffering with diabetes, obesity, hypertension, sleep apnea, pain management and potentially many other areas of healthcare management.
BTCY CATALYSTS
Unveiled our personal medical device kit, Biokit, for integration into our Biotricity ecosystem
Unveiled, Bioheart, a first-of-its kind continuous heart rhythm recorder and personal heart and lifestyle solution
The Company’s Bioheart personal cardiac monitor won TIME’s Best Inventions of 2022.
Awarded $250K NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure.
Surpassed 2 billion recorded and analyzed heartbeats for atrial fibrillation (AFib).
Launched Biocare Cardiac Disease Management Solution after two successful pilots at Oklahoma & Kentucky Clinics.
Continued expansion of our network and maintenance of a 95+% retention rate that together drive Biotricity’s residual revenues.
Operating Highlights for the Q3-FY23 to Date
Signed agreements with two leading US medical device distributors and one GPO
Launched Biocare Cardiac Disease Management Solution which is gaining traction, early adoption, and is provided as a bundled service offering to clinics and hospitals
Q3-FY23 Financial Highlights
Revenue totaled $2.46 million
Gross profit totaled $1.4 million
Gross margin of 57%
Net loss totaled $4.75 million, or $0.091 per share
There is an ongoing shift in healthcare towards preventive care, which Biotricity is leveraging to modernize chronic care & disease management.
The company believes its diagnostic and post-diagnostic solutions help reduce healthcare costs and detect anomalies earlier than existing monitoring solutions and provide faster and better reporting, as well. BTCY has expanded its salesforce in 2022 and targets further penetration into doctor’s offices and clinics with the recent launch of Biotres and the upcoming launch of other products. The company believes its tech platform is disrupting the traditional cardiac care model. With Biotricity’stechnology, cardiac patients can access advanced diagnostics from their homes using Biotricity devices, and thereby minimize visits to the cardiologist or hospital to times when therapeutic treatment or procedures are needed. The company’s lead product, Bioflux, is designed to detect an arrhythmia, heart attack, ventricular or atrial issue faster and transmit the information to a call center to prevent a traumatic health event faster than a conventional Holter device.
As BTCY moves to grow its share in the cardiac health cloud service niche, the company also seeks to expand horizontally beyond the cardiac market. Biotricity believes its emerging ecosystem offers a user- friendly platform that can be applied to help people suffering with diabetes, obesity, hypertension, sleep apnea, pain management and potentially many other areas.
The company launched Biotres earlier this year. It is a wearable wireless 3-lead patch device for continuous recording of ECG heart data and wider array of arrythmia monitoring.
As BTCY initiatives measures to grow its share in the cardiac health cloud service niche, the company also seeks to expand horizontally beyond cardiac and believes its emerging ecosystem offers a user-friendly platform that can be applied to monitor and assist people suffering with diabetes, obesity, hypertension, sleep apnea, pain management and potentially many other areas of healthcare management.
BTCY CATALYSTS
Unveiled our personal medical device kit, Biokit, for integration into our Biotricity ecosystem
Unveiled, Bioheart, a first-of-its kind continuous heart rhythm recorder and personal heart and lifestyle solution
The Company’s Bioheart personal cardiac monitor won TIME’s Best Inventions of 2022.
Awarded $250K NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure.
Surpassed 2 billion recorded and analyzed heartbeats for atrial fibrillation (AFib).
Launched Biocare Cardiac Disease Management Solution after two successful pilots at Oklahoma & Kentucky Clinics.
Continued expansion of our network and maintenance of a 95+% retention rate that together drive Biotricity’s residual revenues.
Operating Highlights for the Q3-FY23 to Date
Signed agreements with two leading US medical device distributors and one GPO
Launched Biocare Cardiac Disease Management Solution which is gaining traction, early adoption, and is provided as a bundled service offering to clinics and hospitals
Q3-FY23 Financial Highlights
Revenue totaled $2.46 million
Gross profit totaled $1.4 million
Gross margin of 57%
Net loss totaled $4.75 million, or $0.091 per share
1
Posted on 4/18/23 at 9:51 am to LatinTiger30
I hope you got in last week.
Posted on 4/18/23 at 4:18 pm to ynlvr
Got in yesterday at .60 and made some money. It’ likely setting up for a squeeze play.
This post was edited on 4/18/23 at 5:44 pm
Posted on 4/19/23 at 10:13 am to LatinTiger30
You are doing well today!
Posted on 4/19/23 at 10:19 am to ynlvr
It’s pumping BIGLY today. Up 17% as of this update and this thing is just getting started.
$7 is the projected top for this squeeze. I’ll get out at $5 with a nice profit. We’ll see, but this is a growing company with lots of positive catalyst. I may keep stock in the company for the long term.
$7 is the projected top for this squeeze. I’ll get out at $5 with a nice profit. We’ll see, but this is a growing company with lots of positive catalyst. I may keep stock in the company for the long term.
This post was edited on 4/19/23 at 10:24 am
Page 1 of 1
Popular
Back to top
Follow TigerDroppings for LSU Football News